Ocumension Therapeutics (HKSE:01477) Long-Term Capital Lease Obligation : HK$6.2 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Ocumension Therapeutics Long-Term Capital Lease Obligation?

Ocumension Therapeutics's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$6.2 Mil.

Ocumension Therapeutics's quarterly Long-Term Capital Lease Obligation declined from Dec. 2022 (HK$19.3 Mil) to Jun. 2023 (HK$12.4 Mil) and declined from Jun. 2023 (HK$12.4 Mil) to Dec. 2023 (HK$6.2 Mil).

Ocumension Therapeutics's annual Long-Term Capital Lease Obligation increased from Dec. 2021 (HK$8.6 Mil) to Dec. 2022 (HK$19.3 Mil) but then declined from Dec. 2022 (HK$19.3 Mil) to Dec. 2023 (HK$6.2 Mil).

Ocumension Therapeutics Long-Term Capital Lease Obligation Historical Data

The historical data trend for Ocumension Therapeutics's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocumension Therapeutics Long-Term Capital Lease Obligation Chart

Ocumension Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

6.29

8.60

19.31

6.19

Ocumension Therapeutics Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial						8.60	29.50	19.31	12.39	6.19

Ocumension Therapeutics (HKSE:01477) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Ocumension Therapeutics Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Ocumension Therapeutics's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Ocumension Therapeutics (HKSE:01477) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocumension Therapeutics (HKSE:01477) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

5DG:Germany

Address

No. 1858 Yinzhongnan Road, Guoxiang Subdistrict, Wuzhong District, Suzhou, Jiangsu, CHN

Website

http://www.ocumension.com

Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.

Ocumension Therapeutics (HKSE:01477) Headlines

No Headlines